D-1537-2014 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-1537-2014 was initiated by Pfizer Inc. on Jul 30, 2014 and is designated Class III. Reason for recall: Failed pH Specification: A pH result of 2.9 was obtained at the 9 month stability test interval at 25C/60%RH. The registered specification for pH is 3.0 - 7.0 The recall status is terminated (terminated Mar 22, 2017). Affected quantity: 93,800 vials.

Recall details

Product Type
Drugs
Report Date
Aug 20, 2014
Initiation Date
Jul 30, 2014
Termination Date
Mar 22, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
93,800 vials

Product description

Depo-Medrol (methylprednisolone acetate injectable suspension USP), 40 mg/ mL, 1 mL Single-Dose Vial, Rx only, Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, New York NY 10017 NDC 0009-3073-03 DEPO-MEDROL methylprednisolone acetate Injectable Suspension USP, 40 mg per mL, 1 mL Single-Dose Vial, Rx ONLY, Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, New York NY 10017, NOVAPLUS is a registered trademark of Novation, LLC NDC 0009-3073-23

Reason for recall

Failed pH Specification: A pH result of 2.9 was obtained at the 9 month stability test interval at 25C/60%RH. The registered specification for pH is 3.0 - 7.0

Distribution pattern

Nationwide

Code information

Lot H43272, H43265 Exp. 09/14

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1537-2014
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1537-2014. Report a data issue: hello@regdatalab.com.